太阳成集团tyc33455cc(股份)有限公司-官方网站
CN
About Ribo
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
Science
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Pipeline
Pipeline
Products
Clinical Trials
Collaboration
BD and Collaboration
Investors
Overview
Careers
Our Culture
Career Development
Recruitment
About Ribo
Science
Pipeline
Collaboration
Investors
Careers
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
About Oligonucleotide Therapeutics
Technological Innovations
Intellectual Property
Pipeline
Products
Clinical Trials
BD and Collaboration
Overview
Our Culture
Career Development
Recruitment
CN
Search
News
About Ribo
International R&D Center
Scientific Advisory Board
Our Culture
News
About Ribo
News
Ribo Closed $40M Series E1 Financing to support global development of the diversified pipelines and continuous advancement of siRNA technologies.
Jul 29,2022
Last : Ribo Announces China CDE Approval of Clinical Trial Application of RBD7022 First-In-Human Clinical Trial in China for Treatment of Hyperlipidemia.
Next : Ribocure Pharmaceuticals Moves Into GoCo Clinic - Putting North Europe in the Spotlight Within Oligonucleotide Therapeutics
Jul 29,2022
